FDA approves third pancrelipase product: Unapproved products illegal to market after April 28.
Traynor
Kate
K
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D003692:Delayed-Action Preparations / Q000008:administration & dosage; D017277:Drug Approval; D010188:Exocrine Pancreatic Insufficiency / Q000188:drug therapy*; D005765:Gastrointestinal Agents / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007223:Infant; D020799:Pancrelipase / Q000008:administration & dosage* / Q000009:adverse effects; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence*
D003692:Delayed-Action Preparations; D005765:Gastrointestinal Agents; D020799:Pancrelipase